Candela Launches Dual-Wavelength Vbeam Pro for Vascular and Dermatologic Conditions

Candela has introduced its latest pulsed dye laser platform, the Vbeam Pro, at the 2025 Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) in Orlando, Florida.

The new system is FDA-cleared for pediatric use and offers dual-wavelength capabilities for broader dermatologic applications. The debut represents the most substantial update to the company’s vascular laser portfolio in decades, according to a press release from the manufacturer. 

The Vbeam Pro integrates a 595 nm pulsed dye laser with a 1064 nm Nd:YAG wavelength, enabling clinicians to treat a wider range of vascular and pigmented lesions. Indications include rosacea, port-wine stains, acne, leg and spider veins, scars, warts, stretch marks, photoaging, and more. According to Candela, the system delivers tighter energy control (up to 30% greater precision) supporting consistent outcomes across all Fitzpatrick skin types.

Vbeam Pro has demonstrated up to 20% improved lesion clearance in studies, representing a 50% reduction in treatment time, and a 20% decrease in reported patient discomfort based on internal data. Enhancements also include an optimized dye system and an improved user interface.

"The Vbeam Pro system is a transformative evolution in pulsed dye laser technology,” said Dr. Roy Geronemus, Clinical Professor in the Department of Dermatology at NYU Grossman School of Medicine and Medical Director of the Vascular Birthmarks Foundation, in the news release. “The clinical results are remarkably consistent, and patients are experiencing enhanced outcomes compared to earlier-generation systems”

Source: Candela press release. April 24, 2025.